Why Inhibikase Therapeutics’ pivotal PAH study may become a major 2026 biotech catalyst
Inhibikase Therapeutics begins pivotal Phase 3 testing of IKT-001 in PAH. Discover what this means for approval odds, clinicians, and investors.
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.
Why Anixa Biosciences’ Phase 2 breast cancer vaccine push matters more than the manufacturing deal itself
Anixa Biosciences is advancing its breast cancer vaccine toward Phase 2 after positive Phase 1 data. Read what this means for oncology watchers.
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.
Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?
Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.
What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy
Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.
Can ZIVO Bioscience finally scale Zivolife after securing Cyanotech as its manufacturing partner?
ZIVO Bioscience’s Cyanotech deal could reshape the Zivolife commercialization story. Read why manufacturing may now matter more than hype.
Why ABION’s ABN202 may be aiming beyond TROP2 antibody-drug conjugate resistance
ABION’s ABN202 showed preclinical promise against TROP2 ADC resistance at AACR 2026. Read what this could mean for solid tumor oncology.